[Effect of hyperhomocysteinemia and methylenetetrahydrofolate reductase 677C --> T mutation in venous thromboembolism risk of young adults].
OBJECTIVE
To investigate whether hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) 677C --> T mutation are associated with venous thromboembolism in young Spanish adults.


METHODS
One hundred adult patients younger than 50 years and 177 controls with similar age and gender.


RESULTS
Hyperhomocysteinemia was present in 21% of the patients and 3.3% of the controls (p < 0.001), and MTHFR 677C --> T mutation was found in 25 and 14.7%, respectively (p = 0.03). Odds ratio (OR) for thromboembolism in hyperhomocysteinemic patients was 7.5 (95% CI, 2.9-19.2; p < 0.001), and in patients with MTHFR 677C --> T mutation the OR was 1.9 (95% CI, 1.1-3.5; p = 0.03). In a subgroup of 76 patients without other thrombogenic factors, thromboembolism persisted associated with hyperhomocysteinemia, yet an association with MTHFR 677C --> T mutation was not confirmed.


CONCLUSIONS
Hyperhomocysteinemia, but not MTHFR 677C --> T mutation, is a risk factor for venous thromboembolism in young adults without other thrombogenic factors.
Fernández-Miranda
Consuelo
C
Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid, Spain. cfmiranda@inicia.es
Coto
Angel
A
Martínez
Joaquín
J
Gómez
Pilar
P
Gómez de la Cámara
Agustín
A
D000328:Adult; D005260:Female; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications*; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D009154:Mutation; D012307:Risk Factors; D013923:Thromboembolism / Q000453:epidemiology* / Q000209:etiology
D006710:Homocysteine; D042965:Methylenetetrahydrofolate Reductase (NADPH2)